Rize ICAV Medical Cannabis & Life Sciences UCITS ETF GBP (FLWG)
4.10p (0.95%) Previous:
|Index:||The Foxberry Medical Cannabis & Life Sciences USD Net Total Return Index (the “Index”) provides exposure to global publicly-traded companies which are involved in the global medical cannabis and cannabis related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors, as determined by the Thematic Industry Expert (Tematica Research), but excluding companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market, as determined in accordance with the Rize Global Medical Cannabis Exclusion List Methodology. The Index rebalances semi-annually. All companies classified as Big Pharma (as defined in the Index Methodology) are given a group weight of 10% and the relevant companies are equally-weighted within that. All other companies are liquidity-weighted subject to a minimum weight per company of 0.05% and a maximum weight per company of 15%.|
The investment objective of the Fund is to provide exposure to publicly-listed...
Read full aim for Rize ICAV
|Ongoing Charge (OCF/TER):||0.65%|
In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.
|ARENA PHARMACEUTICALS INC||16.38%|
|SCOTTS MIRACLE-GRO CO||15.27%|
|CARA THERAPEUTICS INC||9.84%|
|CORBUS PHARMACEUTICALS HLDGS INC||8.02%|
|ZYNERBA PHARMACEUTICALS INC||4.23%|
|NEW AGE BEVERAGES CORP||3.69%|
|CHARLOTTES WEB HOLDINGS INC||2.62%|
Recently viewed shares
Recently viewed investments
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.